S&P Capital IQ Reiterates its BUY Rating on Human Genome Sciences

October 19 00:00 2011

NEW YORK, October 19 (RainbowNewsLine.com) – Analyst Steven Silver of S&P Capital IQ reiterates BUY rating on the shares of Human Genome Sciences (NASDAQ: HGSI).

Analyst Steven Silver, in a research note published yesterday mentions that the company’s share price rose 13% due to an unconfirmed report by UK Daily Mail mentioning GlaxoSmithKline (NYSE: GSK) may be placing a bid of $25 per share to acquire HGSI. GSK is a global partner of HGSI on lupus drug Benlysta and HGSI’s expected to remain volatile since Benlysta is a key value driver, the analyst says. Human Genome Sciences is scheduled to report its Q3 results on October 25.